<DOC>
	<DOCNO>NCT02631239</DOCNO>
	<brief_summary>Extranodal natural killer ( NK ) /T-cell lymphoma ( ENKTL ) , nasal type , distinct heterogeneous histopathologic subtype non-Hodgkin lymphoma ( NHL ) , account 5 % ~10 % . The frequency ENKTL among NHL patient significantly high Asia Western country , poor prognosis . Radiotherapy plus chemotherapy improved survival patient . But optimal treatment schedule controversial . The previous protocol usually contain high dose methotrexate , application limit toxicity .</brief_summary>
	<brief_title>MESA Versus ESA Treatment Early Stage NK/T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Pathological diagnosis extranodal NK/T cell lymphoma , nasal type , previously untreated Age 14 ~ 70 year old ECOG ( Eastern Cooperative Oncology Group）performance status 0~2 Stage I II Life expectancy &gt; 6 month Informed consented Chemotherapy Bone marrow transplantation History malignancy Uncontrollable cardiocerebral vascular , coagulative , autoimmune , serious infectious disease LVEF≤50 % Other uncontrollable medical condition may may interfere participation study Lab enrollment ALT AST &gt; 3*ULN , AKP bilirubin &gt; 2.5*ULN Creatinine &gt; 1.5*ULN Not able comply protocol mental unknown reason Pregnant lactation HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>